March 18, 2010
– Comments (8)
SIRNA was the ticker symbol of Sirna Therapeutics.
Merck Closes $1.1B Sirna Acquisition After RNAi Shop Tentatively Settles Three Lawsuits
Merck's Big Play in RNA
Merck's risky bet on a little biotech
Merck’s Alan Sachs, on RNAi’s Big Challenge: Delivery, Delivery, Delivery
Merck's Sirna Acquisition Adds the Kind of Value Wall Street Doesn't See
Alnylam, RXi On Collision Course Over Intellectual Property From Massachusetts Life Sciences Initiative
Alnylam and RXi: A match made in heaven?
Tekmira shares surge on Pfizer collaboration
Tekmira Pharmaceuticals Provides Corporate Update and Reports 2009 Audited Results
for the hobby scientists ...
Targeted mRNA degradation by double-stranded RNA in vitro
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
zzlangerhans made an "outperform" call on RXII on 03/12/10. So did I on 03/16/10 having looked at it (more of a "casual glance").
#998) On February 12, 2010 at 9:37 PM, portefeuille (99.97) wrote: ALNY - 17.48 - outperform
#1064) On March 15, 2010 at 8:30 PM, portefeuille (99.97) wrote: RXII - 6.59 - outperform
some charts (CYTR is still a "major holder" of RXII shares).
#88) On March 16, 2010 at 2:30 PM, portefeuille (99.97) wrote: TKM:CN - 0.83 (0.84 CAD) - outperform (high risk!)
#1067) On March 18, 2010 at 10:19 AM, portefeuille (99.97) wrote: TKM:CN - 0.89 (0.90 CAD) - outperform
Do you run any kind of technical screen?
It seems like a number of the companies you follow are 50+ RSI, rising volume, EMA crosses of one sort or another, etc.
no, none of that. volume is usually higher than average on the days I make the calls when it is more or less an "event driven" call.
RNAI was the ticker symbol of Sirna Therapeutics.
Cancer genes silenced in humans
Nanotech robots deliver gene therapy through blood
Caltech-led team provides proof in humans of RNA interference using targeted nanoparticles
Research provides proof in humans of RNA interference using targeted nanoparticles
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Mark E. Davis1, Jonathan E. Zuckerman1, Chung Hang J. Choi1, David Seligson2,3, Anthony Tolcher5, Christopher A. Alabi1,8, Yun Yen6, Jeremy D. Heidel7 & Antoni Ribas2,4
Therapeutics that are designed to engage RNA interference (RNAi) pathways have the potential to provide new, major ways of imparting therapy to patients1, 2. Long, double-stranded RNAs were first shown to mediate RNAi in Caenorhabditis elegans3, and the potential use of RNAi for human therapy has been demonstrated by the finding that small interfering RNAs (siRNAs; approximately 21-base-pair double-stranded RNA) can elicit RNAi in mammalian cells without producing an interferon response4. We are at present conducting the first in-human phase I clinical trial involving the systemic administration of siRNA to patients with solid cancers using a targeted, nanoparticle delivery system. Here we provide evidence of inducing an RNAi mechanism of action in a human from the delivered siRNA. Tumour biopsies from melanoma patients obtained after treatment show the presence of intracellularly localized nanoparticles in amounts that correlate with dose levels of the nanoparticles administered (this is, to our knowledge, a first for systemically delivered nanoparticles of any kind). Furthermore, a reduction was found in both the specific messenger RNA (M2 subunit of ribonucleotide reductase (RRM2)) and the protein (RRM2) levels when compared to pre-dosing tissue. Most notably, we detect the presence of an mRNA fragment that demonstrates that siRNA-mediated mRNA cleavage occurs specifically at the site predicted for an RNAi mechanism from a patient who received the highest dose of the nanoparticles. Together, these data demonstrate that siRNA administered systemically to a human can produce a specific gene inhibition (reduction in mRNA and protein) by an RNAi mechanism of action.
good old Caenorhabditis elegans, hehe ...
CALAA-01 Results Indicate RNAi Therapeutics to Revolutionize Solid Cancer Treatment